| Chapter title |
Hybridoma technology for the generation of monoclonal antibodies.
|
|---|---|
| Chapter number | 7 |
| Book title |
Antibody Methods and Protocols
|
| Published in |
Methods in molecular biology, January 2012
|
| DOI | 10.1007/978-1-61779-931-0_7 |
| Pubmed ID | |
| Book ISBNs |
978-1-61779-930-3, 978-1-61779-931-0
|
| Authors |
Zhang C, Chonghui Zhang, Zhang, Chonghui |
| Abstract |
Hybridoma technology has long been a remarkable and indispensable platform for generating high-quality monoclonal antibodies (mAbs). Hybridoma-derived mAbs have not only served as powerful tool reagents but also have emerged as the most rapidly expanding class of therapeutic biologics. With the establishment of mAb humanization and with the development of transgenic-humanized mice, hybridoma technology has opened new avenues for effectively generating humanized or fully human mAbs as therapeutics. In this chapter, an overview of hybridoma technology and the laboratory procedures used routinely for hybridoma generation are discussed and detailed in the following sections: cell fusion for hybridoma generation, antibody screening and characterization, hybridoma subcloning and mAb isotyping, as well as production of mAbs from hybridoma cells. |
X Demographics
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Denmark | 1 | <1% |
| Unknown | 218 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 51 | 23% |
| Student > Master | 36 | 16% |
| Student > Ph. D. Student | 23 | 11% |
| Researcher | 17 | 8% |
| Student > Doctoral Student | 11 | 5% |
| Other | 20 | 9% |
| Unknown | 61 | 28% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 63 | 29% |
| Agricultural and Biological Sciences | 37 | 17% |
| Immunology and Microbiology | 13 | 6% |
| Engineering | 9 | 4% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 4% |
| Other | 25 | 11% |
| Unknown | 64 | 29% |